Sinovac Biotech, Ltd. (SVA)


Stock Price Forecast

Feb. 22, 2019


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sinovac Biotech, Ltd. chart...

About the Company

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.

CEO

Weidong Yin

Exchange

NASDAQ

Website

www.sinovacbio.com

$19B

Total Revenue

2K

Employees

$738M

Market Capitalization

0.09

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SVA News

Gilead CAR-T cancer therapy capacity to quadruple by 2026

on MSN ago, source:

Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the ...

DURIAN DIPLOMACY: MUSANG KING'S SWEET SUCCESS UNITES MALAYSIA AND CHINA IN CULINARY AND CULTURAL EXCHANGE

23y ago, source: bernama

Malaysia has been exporting frozen durian products to China since 2011, achieving 108.9 per cent self-sufficiency in durian production last year, with an output of 455,458 metric tonnes. The annual ...

Positioned to Capitalize on Unprecedented Growth in the Immunostimulants Market is projected to reach US$ 206.96 Billion by 2033

8d ago, source: Future Market Insights

The global immunostimulants market has witnessed an extraordinary surge, reaching a remarkable US$ 113.54 billion in 2023 ...

Global Vaccines Market Research Report 2024: Focus on Commercialized and Developmental Vaccines

8d ago, source:

The "The World Market for Vaccines, 2024" report has been added to ResearchAndMarkets.com's offering. The World Market for Vaccines, 2024 offers the most up-to-date and comprehensive analysis of adult ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...